Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
…of progression to unresectable (meaning it cannot be removed by surgery) melanoma before surgery, disease recurrence (meaning the return of…
Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
…of progression to unresectable (meaning it cannot be removed by surgery) melanoma before surgery, disease recurrence (meaning the return of…
,
Talk to a Medical Expert
Do You Have Questions About Melanoma? AIM at Melanoma knows that a melanoma diagnosis can be confusing, but you don’t…
Women in Melanoma
Women In Melanoma: AIM’s Latest Success Story AIM at Melanoma is always looking for innovative and effective ways to support…
Follow Up By Stage
…leading cancer centers in the U.S. The NCCN panel for melanoma comprises key opinion leaders in melanoma from across the…
Melanoma Int’l Collaboration for Adaptive Trials
…AIM at Melanoma is establishing a global, collaborative, patient-centric, multi-arm clinical trial that will bring effective melanoma therapies to market…
Walks
2024 Steps Against Melanoma Walks Prepare your black awareness attire, as AIM’s Steps Against Melanoma Walks are set to return…
Stanford Health Care | Saturday, September 7, 2024
…Therapy for Advanced Melanoma Allison Betof Warner, MD, PhD (Co-moderator) Assistant Professor, Medicine/Oncology, Stanford University School of Medicine; Co-Director, Pigmented…
From a Scare to Awareness: Lindsay Willis’s Mission to Educate on Melanoma Risks
…Lindsay’s mom thought about her own history with pre-melanomas and insisted her daughter’s mole be removed, just in case. “Thankfully…
,
Annual Report & Financials
…Form 990, 2022 AIM at Melanoma Form 990, 2022 Financial Statements & Notes 2021 AIM at Melanoma 2021 Financial Statements…
Surgery
What Type of Surgery Is Performed to Remove Melanoma? Surgery is the first treatment step for the majority of melanomas,…
Recent Posts
Sep. 15, 2024
Long-term Results Continue to Show a Benefit with Nivolumab and Ipilimumab
Sep. 15, 2024
Ten Years of Pembrolizumab Shows Sustained Results
Sep. 15, 2024
Oncolytic Virotherapy Shows Promise in Advanced Melanoma that Failed Immunotherapy
Sep. 15, 2024
New Therapies Under Investigation for Patients With Metastatic Uveal Melanoma
Sep. 14, 2024